Remove 2015 Remove Clinical Pharmacology Remove Labelling
article thumbnail

AbbVie extends Gedeon Richter alliance that gave it Vraylar

pharmaphorum

Vraylar, sold in some markets as Reagila, was first approved in 2015 for schizophrenia and bipolar disorder, with its label extended in 2017 to include maintenance treatment of schizophrenia and again in 2019 for bipolar depression.

article thumbnail

Top 9 Takeaways From 2232 People With Hashimoto’s

The Thyroid Pharmacist

Unfortunately, these types of clinical trials can be very expensive, and there isn’t a financial incentive for most companies to do this kind of research if they can’t collect a return on their investment. Then in 2015, I realized that we, the thyroid community, have the power to conduct our own research! Asia Pac J Clin Nutr.